During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk ...

Panelists discuss how clinical trial data from the COMFORT studies supports using Janus kinase (JAK) inhibitors such as ...

Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred.

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Eli Lilly’s Olumiant is a first-in-class Janus kinase (JAK)1/2 inhibitor that was approved across the EU and Japan in 2020.